The following is a summary of the Indivior PLC (INDV) Q3 2024 Earnings Call Transcript:

Financial Performance:

• Indivior PLC reported a 13% increase in Q3 net revenue to $307 million.

• Adjusted operating profit rose by 62% to $97 million.

• Gross margin stood at 82%, though this marked a sequential and year-over-year decline due to cost inflation.

• SUBLOCADE's net revenue for the quarter was $191 million, up 14% from the previous year.

Business Progress:

• SUBLOCADE U.S. patients and treatment grew 37% year-over-year to 166,600.

• The number of active dispensing HCPs for SUBLOCADE increased by 15% to over 7,700.

• Indivior added one new partner, bringing the total number of alternate injection sites to about 1,220.

• Indivior is focusing on streamlining actions targeting cost reduction in G&A and reprioritizing the R&D pipeline.

Opportunities:

• Established approximately 180 experiential programs for OPVEE and 32 states now have standing orders in place.

• Indivior confirmed a 10-year contract with BARDA involving net revenue from two orders within the quarter.

Risks:

• SUBLOCADE's growth being impacted by intensified initial trial and adoption of competing products, variability in funding, and further destocking in certain justice system accounts.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.